Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

Leonardo M Fabbri, Peter M A Calverley, José Luis Izquierdo-Alonso, Daniela S Bundschuh, Manja Brose, Fernando J Martinez, Klaus F Rabe, M2-127 and M2-128 study groups, Bill Macnee

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated.
Original languageEnglish
Pages (from-to)695-703
Number of pages9
JournalThe Lancet
Volume374
Issue number9691
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials'. Together they form a unique fingerprint.

Cite this